Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Vaccines - the key paradigm for the 21st century's health care strategy: 5th Semmering vaccine symposium, Baden/Vienna. Editorial.

Alkan SS, Decker T, von Gabain A.

Vaccine. 2012 Jun 19;30(29):4299-300. doi: 10.1016/j.vaccine.2012.03.077. Epub 2012 Mar 30. No abstract available.

PMID:
22464968
2.

Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination.

Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP.

Vaccine. 2012 Apr 19;30(19):2943-50. doi: 10.1016/j.vaccine.2012.02.070. Epub 2012 Mar 6.

PMID:
22401867
3.

Straight talk with...Alexander von Gabain. Interview by Hannah Waters.

von Gabain A.

Nat Med. 2011 Sep 7;17(9):1029. doi: 10.1038/nm0911-1029. No abstract available.

PMID:
21900907
4.

Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner.

Senn BM, Visram Z, Meinke AL, Neubauer C, Gelbmann D, Sinzinger J, Hanner M, Lundberg U, Boisvert H, Reinscheid D, von Gabain A, Nagy E.

Vaccine. 2011 May 31;29(24):4116-24. doi: 10.1016/j.vaccine.2011.03.100. Epub 2011 Apr 13.

PMID:
21496467
5.

Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells.

Aichinger MC, Ginzler M, Weghuber J, Zimmermann L, Riedl K, Schütz G, Nagy E, von Gabain A, Schweyen R, Henics T.

Vaccine. 2011 Jan 10;29(3):426-36. doi: 10.1016/j.vaccine.2010.11.003. Epub 2010 Nov 18.

PMID:
21093498
6.

Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens.

Meinke AL, Senn BM, Visram Z, Henics TZ, Minh DB, Schüler W, Neubauer C, Gelbmann D, Noiges B, Sinzinger J, Hanner M, Dewasthaly S, Lundberg U, Hordnes K, Masoud H, Sevelda P, von Gabain A, Nagy E.

Vaccine. 2010 Oct 8;28(43):6997-7008. doi: 10.1016/j.vaccine.2010.08.041. Epub 2010 Aug 21.

PMID:
20732466
7.

Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Fritzer A, Senn BM, Minh DB, Hanner M, Gelbmann D, Noiges B, Henics T, Schulze K, Guzman CA, Goodacre J, von Gabain A, Nagy E, Meinke AL.

Infect Immun. 2010 Sep;78(9):4051-67. doi: 10.1128/IAI.00295-10. Epub 2010 Jul 12.

8.

Innovating vaccines: from gene expression to translational entrepreneurship.

von Gabain A.

Hum Vaccin. 2010 Feb;6(2):164-8. Epub 2010 Feb 24.

PMID:
20424513
9.

The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections?

Giefing C, Nagy E, von Gabain A.

Adv Exp Med Biol. 2009;655:90-117. doi: 10.1007/978-1-4419-1132-2_9. Review.

PMID:
20047038
10.

Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.

Prchal M, Pilz A, Simma O, Lingnau K, von Gabain A, Strobl B, Müller M, Decker T.

Vaccine. 2009 Dec 30;27 Suppl 6:G17-20. doi: 10.1016/j.vaccine.2009.10.016. Review.

PMID:
20006134
11.

Novel vaccines: entrepreneurial contributions and scientific challenges.

von Gabain A.

Vaccine. 2009 Dec 30;27 Suppl 6:G1-2. doi: 10.1016/j.vaccine.2009.10.030. No abstract available.

PMID:
20006132
12.

[Novel vaccination concepts on the basis of modern insights into immunology].

Kaufmann SH, Meinke AL, von Gabain A.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Nov;52(11):1069-82. doi: 10.1007/s00103-009-0951-0. German.

PMID:
19838650
13.

Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL.

Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K, von Gabain A, Stoiber D, Sexl V, Kolbe T, Rülicke T, Müller M, Decker T.

J Immunol. 2009 Aug 15;183(4):2286-93. doi: 10.4049/jimmunol.0901383. Epub 2009 Jul 20.

14.

Chemokine degradation by the Group A streptococcal serine proteinase ScpC can be reconstituted in vitro and requires two separate domains.

Fritzer A, Noiges B, Schweiger D, Rek A, Kungl AJ, von Gabain A, Nagy E, Meinke AL.

Biochem J. 2009 Aug 27;422(3):533-42. doi: 10.1042/BJ20090278.

PMID:
19552626
15.

Helices alpha2 and alpha3 of West Nile virus capsid protein are dispensable for assembly of infectious virions.

Schlick P, Taucher C, Schittl B, Tran JL, Kofler RM, Schueler W, von Gabain A, Meinke A, Mandl CW.

J Virol. 2009 Jun;83(11):5581-91. doi: 10.1128/JVI.02653-08. Epub 2009 Mar 18.

16.

Composition of the ANTIGENome of Helicobacter pylori defined by human serum antibodies.

Meinke A, Storm M, Henics T, Gelbmann D, Prustomersky S, Kovács Z, Minh DB, Noiges B, Stierschneider U, Berger M, von Gabain A, Engstrand L, Nagy E.

Vaccine. 2009 May 26;27(25-26):3251-9. doi: 10.1016/j.vaccine.2009.01.066. Epub 2009 Feb 5.

PMID:
19200834
17.

[Therapeutic vaccines against cancer and infectious diseases. Great possibilities in the research--small clinical progress so far].

Kiessling R, Ljungberg K, Von Gabain A.

Lakartidningen. 2008 Sep 3-9;105(36):2402-4. Swedish. No abstract available.

PMID:
18831450
18.

Unique membrane-interacting properties of the immunostimulatory cationic peptide KLKL(5)KLK (KLK).

Aichinger MC, Ortbauer M, Reipert S, Zauner W, Bogner P, Froschauer E, Nowikovsky K, Lingnau K, von Gabain A, Schweyen R, Henics T.

Cell Biol Int. 2008 Nov;32(11):1449-58. doi: 10.1016/j.cellbi.2008.08.024. Epub 2008 Aug 30.

PMID:
18771740
19.

Novel paradigms in vaccine development: from small pox eradication to therapeutic vaccines.

von Gabain A, Nagy E, Decker T.

Biol Chem. 2008 May;389(5):455-6. doi: 10.1515/BC.2008.067. No abstract available.

PMID:
18605920
20.

The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.

Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K.

Vaccine. 2008 Jun 25;26(27-28):3461-8. doi: 10.1016/j.vaccine.2008.04.029. Epub 2008 May 5.

PMID:
18495302
21.

Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells.

Kamath AT, Valenti MP, Rochat AF, Agger EM, Lingnau K, von Gabain A, Andersen P, Lambert PH, Siegrist CA.

Eur J Immunol. 2008 May;38(5):1247-56. doi: 10.1002/eji.200737889.

22.

Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases.

Nagy E, Giefing C, von Gabain A.

Expert Rev Anti Infect Ther. 2008 Feb;6(1):21-30. doi: 10.1586/14787210.6.1.21. Review.

PMID:
18251661
23.

Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies.

Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, Lundberg U, Senn BM, Schunn M, Habel A, Henriques-Normark B, Ortqvist A, Kalin M, von Gabain A, Nagy E.

J Exp Med. 2008 Jan 21;205(1):117-31. doi: 10.1084/jem.20071168. Epub 2007 Dec 31.

24.

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.

Lingnau K, Riedl K, von Gabain A.

Expert Rev Vaccines. 2007 Oct;6(5):741-6. Review.

PMID:
17931154
25.

High-affinity binding of the staphylococcal HarA protein to haptoglobin and hemoglobin involves a domain with an antiparallel eight-stranded beta-barrel fold.

Dryla A, Hoffmann B, Gelbmann D, Giefing C, Hanner M, Meinke A, Anderson AS, Koppensteiner W, Konrat R, von Gabain A, Nagy E.

J Bacteriol. 2007 Jan;189(1):254-64. Epub 2006 Oct 13.

26.

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses.

Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, Swatosch G, Zauner W, Kast C, Akira S, von Gabain A, Buschle M, Lingnau K.

Vaccine. 2006 Jun 29;24(26):5461-72. Epub 2006 Apr 7.

PMID:
16678312
27.

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, Kritsch C, Lingnau K, von Gabain A, Andersen CS, Korsholm KS, Andersen P.

Vaccine. 2006 Jun 29;24(26):5452-60. Epub 2006 Apr 17.

PMID:
16675077
28.

Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism.

Säemann MD, Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von Gabain A, von Ahsen U, Hörl WH, Zlabinger GJ.

J Clin Invest. 2005 Feb;115(2):468-75.

29.

Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage.

Hagens S, Habel A, von Ahsen U, von Gabain A, Bläsi U.

Antimicrob Agents Chemother. 2004 Oct;48(10):3817-22.

30.

PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome.

Lachmann M, Gelbmann D, Kálmán E, Polgár B, Buschle M, Von Gabain A, Szekeres-Barthó J, Nagy E.

Int J Cancer. 2004 Oct 20;112(1):51-60.

31.

Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro.

Weichhart T, Horky M, Söllner J, Gangl S, Henics T, Nagy E, Meinke A, von Gabain A, Fraser CM, Gill SR, Hafner M, von Ahsen U.

Infect Immun. 2003 Aug;71(8):4633-41.

32.

Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens.

Henics T, Winkler B, Pfeifer U, Gill SR, Buschle M, von Gabain A, Meinke AL.

Biotechniques. 2003 Jul;35(1):196-202, 204, 206 passim.

33.

European biotech hasn't hit the street.

Von Gabain A, Lanthaler W.

EMBO Rep. 2003 Jul;4(7):642-6. No abstract available.

34.
35.

In-gel analysis of site-specific rnases.

Nilsson RP, von Gabain A, Kaberdin VR.

Biotechniques. 2002 Aug;33(2):272, 274, 276. No abstract available.

36.

Selection of peptide entry motifs by bacterial surface display.

Taschner S, Meinke A, von Gabain A, Boyd AP.

Biochem J. 2002 Oct 15;367(Pt 2):393-402.

37.

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.

Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, Boyd AP, Söllner J, Schmidt W, von Ahsen U, Buschle M, Gill SR, Kolonay J, Khalak H, Fraser CM, von Gabain A, Nagy E, Meinke A.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6573-8. Epub 2002 May 7.

38.
40.

Defined synthetic vaccines.

Zauner W, Lingnau K, Mattner F, von Gabain A, Buschle M.

Biol Chem. 2001 Apr;382(4):581-95. Review.

PMID:
11405222
41.

Vaccine development: from empirical medicine to molecularly designed therapy.

Buschle M, Mattner F, Zauner W, von Gabain A.

Biol Chem. 2001 Apr;382(4):505. No abstract available.

PMID:
11405215
42.

Cleavage of poly(A) tails on the 3'-end of RNA by ribonuclease E of Escherichia coli.

Walsh AP, Tock MR, Mallen MH, Kaberdin VR, von Gabain A, McDowall KJ.

Nucleic Acids Res. 2001 May 1;29(9):1864-71.

43.

Enhanced cleavage of RNA mediated by an interaction between substrates and the arginine-rich domain of E. coli ribonuclease E.

Kaberdin VR, Walsh AP, Jakobsen T, McDowall KJ, von Gabain A.

J Mol Biol. 2000 Aug 11;301(2):257-64.

PMID:
10926508
44.

Hfq (HF1) stimulates ompA mRNA decay by interfering with ribosome binding.

Vytvytska O, Moll I, Kaberdin VR, von Gabain A, Bläsi U.

Genes Dev. 2000 May 1;14(9):1109-18.

45.

Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability.

Henics T, Nagy E, Oh HJ, Csermely P, von Gabain A, Subjeck JR.

J Biol Chem. 1999 Jun 11;274(24):17318-24.

46.

Growth phase-regulated induction of Salmonella-induced macrophage apoptosis correlates with transient expression of SPI-1 genes.

Lundberg U, Vinatzer U, Berdnik D, von Gabain A, Baccarini M.

J Bacteriol. 1999 Jun;181(11):3433-7.

48.

Max, the Vienna Biocenter and other 'spin-off'.

von Gabain A.

Biol Chem. 1999 Feb;380(2):115-6. No abstract available.

PMID:
10195417
50.

Host factor I, Hfq, binds to Escherichia coli ompA mRNA in a growth rate-dependent fashion and regulates its stability.

Vytvytska O, Jakobsen JS, Balcunaite G, Andersen JS, Baccarini M, von Gabain A.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14118-23.

Supplemental Content

Loading ...
Support Center